Support NET Research
The Neuroendocrine Tumor Research Foundation (NETRF) is the leading funder of neuroendocrine tumor (NET) research, having funded more than $30 million in research projects aimed at advancing improved treatments for neuroendocrine tumors. NETRF funds are solely provided by private donations from around the globe. There are many ways to support neuroendocrine tumor (NET) research, such a making a gift, volunteering, or hosting a fundraising event. We hope that the information you find on this page is helpful and will entice you to take the next step in getting involved with NETRF.
Your gift will fund world-class research, empower and educate NET survivors and families and bolster the field of NET research. Learn more about the impact of your gift .
COVID-19 — We Need Your Help
With COVID-19 affecting families around the globe, NETRF needs your support now more than ever. While we all adjust to different routines of school closings, working from home, and cancellation of activities, NET research must continue and not slow down. Giving online is a simple and safe way to make your donation today. Please visit our Give Now page to support NET research. Thank you!
For questions about making your gift, please contact Susan Payson, Chief Development Officer at susan.payson@netrf.org.
The latest in NET News
Research Spotlight: Rodney Hicks, MD
Peptide receptor radionuclide therapy, or PRRT, has been available as a treatment option for some forms of neuroendocrine tumors – particularly for those NETs expressing the somatostatin receptor-2 (SSTR2) protein.
New Clinical Trial Focuses on Lutathera® in Adolescents with NETs
A phase II clinical trial has launched to study Lutathera® in adolescents with gastroenterpancreatic neuroendocrine tumors (GEP-NET), pheochromocyomas and paragangliomas (PPGLs).
NETRF Announces Changes to its Board of Scientific Advisors
The Neuroendocrine Tumor Research Foundation (NETRF) recently announced changes to the Board of Scientific Advisors (BOSA), extending its sincerest appreciation for the participation of Dung Thi Le, MD, and welcoming Jennifer Eads, MD